 |
|
|
| |
Reductions in Lifetime Risks of Liver-Related Morbidity and Mortality Associated with Novel Direct-Acting Antiviral Regimens Recommended for Treating Genotype 4 Non-Cirrhotic Hepatitis C Patients in the United States
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Sammy Saab1, Helene Parise2, Suchin Virabhak2, Alice Wang3, Steven E. Marx3, Scott J. Johnson2
1Pfleger Liver Institute, University of California at Los Angeles, Los Angeles, CA, USA; 2Medicus Economics LLC, Milton, MA, USA; 3AbbVie Inc., North Chicago, IL, USA
|
| |
|
|
|
|
|
